Premium
Lectin binding and expression of blood group‐related antigens in carcinoma‐ in‐situ and invasive carcinoma of urinary bladder
Author(s) -
NAKANISHI K.,
KAWAI T.,
SUZUKI M.
Publication year - 1993
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1993.tb00473.x
Subject(s) - carcinoma in situ , antigen , pathology , transitional cell carcinoma , urinary bladder , carcinoma , bladder cancer , immunohistochemistry , biology , cancer , immunology , medicine
To determine whether histochemical reactivities of carcinoma‐ in‐situ of the urinary bladder differ from those of invasive transitional cell carcinoma, we tested a profile of eight different lectins and three antibodies directed against blood group‐related antigens for 15 cases of carcinoma‐ in‐situ and 26 cases of non‐papillary (6 superficially and 20 deeply) invasive transitional cell carcinoma that had been diagnosed according to the histopathological criteria of the International Union against Cancer. For biotin‐labelled lectins and monoclonal antibodies to mouse blood group‐related antigens, the avidin–biotin peroxidase complex method was applied. Positive histochemical reactions of peanut agglutinin without neuraminidase treatment—PNA N(–)—in the 20 deeply invasive tumour cases were significantly higher than those in the 15 carcinoma‐ in‐situ cases ( P <0.05). In contrast, the reactions of blood group‐related antigens in the 20 deeply invasive tumour cases were significantly lower than those in the 15 carcinoma‐ in‐situ cases or the 11 normal controls ( P <0.05). The results confirm previously reported studies of the staining of PNA N(–) and blood group‐related antigens on carcinoma‐ in‐situ and invasive tumours of urothelial organs. The application of lectins and blood group‐related antigens to the histopathology of urinary bladder cancer may be helpful in the differential diagnosis of carcinoma‐ in‐situ from invasive cancer, but neither PNA N(–) nor blood group‐related antigens can be solely reliable in this.